Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
Notable Analyst Rating Changes 7/14: (GSK) (RRC) (SO) Upgraded; (ATW) (BRCD) (INFO) Downgraded
-
Pre-Open Stock Movers 07/14: (SUNW) (CREE) (YUM) (JPM) Higher; (ACHN) (LXU) (SUM) Lower (more...)
-
UPDATE: Chardan Capital Starts Achillion Pharma (ACHN) at Sell; Tough Competition, Lack of Data Pose Challenges
-
MTBC Announces Closing of $1.6 million of Additional Non-convertible Series A Cumulative Redeemable Perpetual Preferred Stock Offering
-
M III Acquisition Corp. Announces Closing Of Initial Public Offering
-
Chardan Capital Markets Starts Akari Therapeutics (AKTX) at Sell
-
Notable Analyst Rating Changes 7/8: (CF) (COF) (GFI) Upgraded; (AINV) (HUM) (ABUS) Downgraded
-
Chardan Capital Markets Downgrades Arbutus Biopharma (ABUS) to Sell
-
M III Acquisition (MIII) Prices 15M Units IPO for Proceeds of $150M
-
M III Acquisition Corp. Announces Pricing of $150 Million Initial Public Offering
-
MTBC Files Prospectus Supplement
-
BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over-Allotment Option
-
Northwest Biotherapeutics (NWBO) Enters $3.7M Registered Direct Offering
-
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $3.7 MILLION WITH NEW INSTITUTIONAL INVESTORS
-
Regulus Therapeutics (RGLS) PT Cut to $13.50 at Chardan Capital Following Clinical Hold
-
Chardan Capital Markets Starts NICE Systems Ltd (NICE) at Buy
-
BioTime, Inc. Announces Closing of Public Offering of Common Stock
-
Notable Analyst Rating Changes 6/20: (YELP) (SAVE) (SYMC) Upgraded; (EGRX) (SCTY) (ESRX) Downgraded
-
UPDATE: Chardan Capital Markets Starts ProQR Therapeutics N.V. (PRQR) at Neutral
-
BioTime (BTX) Prices 7.3M Stock Offering at $2.39/Share
-
BioTime, Inc. Announces Pricing of Public Offering of Common Stock
-
UPDATE: Chardan Capital Markets Upgrades Arbutus Biopharma (ABUS) to Neutral
-
Chardan Capital Sees New Reasons Regeneron (REGN) Praluent Could be Bemoved from the US Market in 2016
-
Notable Analyst Rating Changes 6/13: (ENDP) (NGL) (CVE) Upgraded; (GSAT) (LYB) (HCLP) Downgraded
-
UPDATE: Chardan Capital Markets Downgrades Globalstar (GSAT) to Neutral
-
AB Science will hold an Investor & Analyst conference on masitinib in Amyotrophic Lateral Sclerosis (ALS) in New York, USA, on June 13, 2016
-
UPDATE: Chardan Capital Markets Downgrades Adverum Biotechnologies (ADVM) to Neutral
-
Covata Completes AU$13.2 Million Private Placement of Common Stock to U.S. and Asia-Pac Institutional Investors
-
Chardan Capital Markets Downgrades KVH Industries (KVHI) to Neutral
-
Unusual 11 Mid-Day Movers 5/24: (SPEX) (XCO) (APHB) Higher; (CLRB) (DSW) (UNIS) Lower
-
Notable Analyst Rating Changes 5/24: (SQ) (MSFT) (DE) Upgraded; (TWTR) (CF) (CYH) Downgraded
-
Pre-Open Stock Movers 05/24: (MGN) (XCO) (PLCM) (GPRO) Higher; (SSW) (DSW) (SAGE) (BBY) Lower (more...)
-
Chardan Capital Markets Starts Sage Therapeutics (SAGE) at Sell
-
Form REVOKED CHARDAN CHINA ACQUISITIO
-
Chardan Capital Markets Starts Asterias Biotherapeutics (AST) at Buy
-
UPDATE: Chardan Capital Markets Starts Arrowhead Research (ARWR) at Buy
-
Inventergy Raises $1.3 Million in a Registered Direct Offering
-
VistaGen Completes $10 Million Public Offering
-
UPDATE: Notable Analyst Rating Changes 5/16: (NOK) (JCP) (BBT) Upgraded; (DB) (BLOX) (BITA) Downgraded
-
Chardan Capital Markets Starts Arbutus Biopharma (ABUS) at Sell
-
VistaGen Announces Nasdaq Listing and Pricing of $10.0 Million Public Offering
-
Jensyn Acquisition Corp. Announces Termination of Over-Allotment Option and Common Stock, Rights and Warrants to Commence Separate Trading on or about April 25, 2016
-
Amarantus Announces Capital Infusion
-
The PIPEs Report Sees Small-Cap Equity Financing Growth at the End of Q1 2016
-
Chardan Capital Markets Starts Emergent BioSolutions (EBS) at Buy
-
Majesco Entertainment (COOL) Entesr $1.5M Registered Direct Offering
-
Majesco Entertainment Announces Above Market Registered Direct Offering
-
Spark Therapeutics (ONCE) Patent Concerns are Resolving - Chardan Capital Markets
-
Chardan Capital Markets Starts Regulus Therapeutics (RGLS) at Buy, $15 PT
-
Pre-Open Stock Movers 04/12: (FOLD) (ARNA) (HLX) Higher; (HZNP) (OZM) (JNPR) Lower (more...)

